Impact of amlodipine-based therapy on blood pressure time in target range in Chinese adults with primary hypertension: a retrospective study.

IF 1.8 4区医学

Blood Pressure Pub Date : 2025-12-01 Epub Date: 2025-06-05 DOI:10.1080/08037051.2025.2510317

Hongyi Wang, Yuqing Zhang, Jinxiu Lin, Yan Shu, Peili Bu, Zhaohui Wang, Wei Song, Yi Zhang, Wei Yu, Ningling Sun

{"title":"Impact of amlodipine-based therapy on blood pressure time in target range in Chinese adults with primary hypertension: a retrospective study.","authors":"Hongyi Wang, Yuqing Zhang, Jinxiu Lin, Yan Shu, Peili Bu, Zhaohui Wang, Wei Song, Yi Zhang, Wei Yu, Ningling Sun","doi":"10.1080/08037051.2025.2510317","DOIUrl":null,"url":null,"abstract":"Background: Recently, both international and Chinese guidelines have mentioned for the first time that blood pressure (BP) target range is more reasonable and workable than BP target in clinical practice, and time in target range (TTR) could become a potential evaluation indicator for long-term blood pressure management. Until now, there was no research on the long-term effects of antihypertensive treatment on systolic BP (SBP) TTR. The objective, therefore, is to observe the impact of long-acting calcium channel blockers (CCBs) on BP TTR in Chinese patients with hypertension (HTN).Methods: A retrospective observational study was conducted using data from the China Cardiovascular Association Hypertension Centre, including 36,153 adult patients diagnosed with primary HTN and treated with amlodipine-based antihypertensive therapy between 1 January 2018 and 31 December 2022. The primary endpoint was the SBP TTR. Other endpoints included the annual trend of SBP TTR, factors influencing SBP TTR, etc.Results: Results showed an overall SBP TTR was 80.42 ± 21.97%. The SBP TTR at 1, 2 and 3 years of follow-up was 79.49 ± 26.16%, 81.86 ± 25.10% and 82.79 ± 25.77%, respectively, showing a significant difference (p < 0.001). Seven factors were positively correlated with SBP TTR, while three factors were negatively correlated with SBP TTR including heart failure, high baseline SBP level, and high LDL-C level.Conclusion: Long-term and continuous use of amlodipine-based antihypertensive therapy could improve SBP TTR. This finding may relate to the characteristic of amlodipine which is a long-acting drug due to pharmacokinetic properties.Trial registration: Chinese Clinical Trial Registry Identifier: ChiCTR2400090150.","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2510317"},"PeriodicalIF":1.8000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Pressure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08037051.2025.2510317","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Recently, both international and Chinese guidelines have mentioned for the first time that blood pressure (BP) target range is more reasonable and workable than BP target in clinical practice, and time in target range (TTR) could become a potential evaluation indicator for long-term blood pressure management. Until now, there was no research on the long-term effects of antihypertensive treatment on systolic BP (SBP) TTR. The objective, therefore, is to observe the impact of long-acting calcium channel blockers (CCBs) on BP TTR in Chinese patients with hypertension (HTN).

Methods: A retrospective observational study was conducted using data from the China Cardiovascular Association Hypertension Centre, including 36,153 adult patients diagnosed with primary HTN and treated with amlodipine-based antihypertensive therapy between 1 January 2018 and 31 December 2022. The primary endpoint was the SBP TTR. Other endpoints included the annual trend of SBP TTR, factors influencing SBP TTR, etc.

Results: Results showed an overall SBP TTR was 80.42 ± 21.97%. The SBP TTR at 1, 2 and 3 years of follow-up was 79.49 ± 26.16%, 81.86 ± 25.10% and 82.79 ± 25.77%, respectively, showing a significant difference (p < 0.001). Seven factors were positively correlated with SBP TTR, while three factors were negatively correlated with SBP TTR including heart failure, high baseline SBP level, and high LDL-C level.

Conclusion: Long-term and continuous use of amlodipine-based antihypertensive therapy could improve SBP TTR. This finding may relate to the characteristic of amlodipine which is a long-acting drug due to pharmacokinetic properties.

Trial registration: Chinese Clinical Trial Registry Identifier: ChiCTR2400090150.

查看原文本刊更多论文

氨氯地平治疗对中国成人原发性高血压患者目标范围内血压时间的影响：一项回顾性研究

近年来，国际和国内的指南均首次在临床实践中提到血压目标范围比血压目标更合理可行，目标范围内时间（time in target range， TTR）可能成为长期血压管理的潜在评价指标。迄今为止，还没有关于抗高血压治疗对收缩压（SBP） TTR的长期影响的研究。因此，目的是观察长效CCBs对中国高血压患者BP TTR的影响。方法采用中国心血管协会高血压中心的数据进行回顾性观察研究，纳入2018年1月1日至2022年12月31日期间诊断为原发性高血压并接受氨氯地平降压治疗的36153例成人患者。主要终点是收缩压TTR。其他终点包括收缩压TTR的年趋势、影响收缩压TTR的因素等。结果总收缩压TTR为80.42±21.97%。随访1年、2年、3年收缩压TTR分别为79.49±26.16%、81.86±25.10%、82.79±25.77%，差异有统计学意义（p < 0.05）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Pressure Medicine-Cardiology and Cardiovascular Medicine

CiteScore

3.20

自引率

5.60%

发文量

期刊介绍： For outstanding coverage of the latest advances in hypertension research, turn to Blood Pressure, a primary source for authoritative and timely information on all aspects of hypertension research and management. Features include: • Physiology and pathophysiology of blood pressure regulation • Primary and secondary hypertension • Cerebrovascular and cardiovascular complications of hypertension • Detection, treatment and follow-up of hypertension • Non pharmacological and pharmacological management • Large outcome trials in hypertension.